5月29日 - ** 制药公司MannKind（MNKD.O）股价上涨5.1%，报3.82美元
** 该公司表示，美国食品药品监督管理局（FDA）已批准其吸入式胰岛素Afrezza（(link)）的适应症扩展，适用于6岁及以上患有1型或2型糖尿病的儿童和青少年
** Afrezza通过小型吸入器给药，为18岁以下患者提供了一种无针治疗方案
** 公司表示，符合条件的患者每月只需支付35美元或更少即可获得Afrezza
** 计入本日股价变动后，MNKD今年以来累计跌幅达32.5%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.